Anixa Biosciences Secures Landmark Breast Cancer Vaccine Patent in South Korea

Anixa Biosciences, Inc., a biotechnology company focused on innovative cancer treatments, has recently achieved a significant milestone by securing its first Korean patent for a breast cancer vaccine. This important development, announced on June 29, 2026, follows the issuance of Patent Number 10-2960889 by the Korean Ministry of Intellectual Property (MOIP). The patent, which protects Anixa's unique approach to combating breast cancer, will remain in effect until 2040, thereby extending the company's global intellectual property portfolio.

The importance of this patent cannot be overstated, particularly in an era where breast cancer is among the most common cancers diagnosed in women across the globe. In South Korea, the incidence of breast cancer is rising, with many cases arising in younger patients, highlighting the urgent need for preventive measures such as this innovative vaccine. The composition-of-matter patent is exclusive to Anixa and is based on technology licensed from Cleveland Clinic.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed enthusiasm about this achievement, stating, "Each global patent we secure deepens the foundation we are building for our breast cancer vaccine." This patent not only reinforces the company's leadership in cancer immunotherapy but also enhances its ability to seek regulatory approvals and strategic partnerships in future commercial endeavors.

Anixa's breast cancer vaccine operates by immunizing against human α-lactalbumin, a protein that is typically associated with lactation but is aberrantly expressed in certain breast cancer forms. This innovative strategy is designed to selectively stimulate the immune system to prevent tumor formation, thus avoiding damage to normal tissue—especially crucial in aggressive variants of the disease such as triple-negative breast cancer.

The company has previously reported impressive outcomes from its Phase 1 clinical trials, where the vaccine was shown to be safe and well-tolerated, with immune responses generated in 74% of the participants. These promising results support continued clinical development and validation of this groundbreaking preventive therapy.

Furthermore, Anixa's expanded patent coverage aims to establish a strong international presence, particularly in markets experiencing higher breast cancer incidences. With this strategic move, the company enhances its potential to collaborate with larger pharmaceutical firms and pursue commercialization opportunities, thereby expanding the reach of its innovative treatments globally.

As breast cancer remains a critical health issue—especially in regions like South Korea, where survival rates are high yet incidence rates are climbing—Anixa's efforts could represent a transformative advancement in preventive strategies against this pervasive disease. The potential implications extend beyond South Korea, as the company's broader vaccine platform targets various high-incidence cancers, promising to redefine cancer prevention approaches in the medical community.

In summary, Anixa Biosciences is paving the way for innovative therapies that address pressing healthcare challenges. By safeguarding its intellectual property rights and demonstrating clinical efficacy, the company is well-positioned to lead in the field of cancer prevention and treatment, marking a hopeful direction for many facing breast cancer and other malignancies.

To stay updated on Anixa's progression and learn more about their cutting-edge solutions, visit Anixa's website or engage with their social media channels on LinkedIn, X, Facebook, and YouTube.